Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Jul;48(7):626–630. doi: 10.1136/jcp.48.7.626

OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.

C Edwards 1, J Oates 1
PMCID: PMC502712  PMID: 7560168

Abstract

AIMS--To investigate the reaction of antibodies OV 632 and MOC 31 in paraffin wax sections as opposed to frozen sections and cytological preparations; to evaluate their usefulness in the differential diagnosis of malignant mesothelioma and secondary adenocarcinoma of the pleura; and to assess the efficacy of microwave pretreatment of sections in unmasking their associated epitopes. METHODS--Immunohistochemistry, using a standard avidin-biotin technique, with microwave pretreatment and trypsinisation in a certain proportion of cases. The material comprised 43 mesotheliomas, 44 adenocarcinomas and five reactive pleuras. RESULTS--Epithelial mesotheliomas and the hyperplastic mesothelial cells reacted strongly with OV 632, the reaction with sarcomatoid and desmoplastic tumours was weak, and the reaction with adenocarcinomas was variable. An unequivocal but sometimes patchy positive reaction was obtained with MOC 31 in all but one of the adenocarcinomas; all but one of the mesotheliomas and all the reactive pleuras were negative. Review of the two apparently anomalous cases revealed that the original diagnoses had probably been incorrect. Reactions to both antibodies were abolished by microwave pretreatment, and also by prior trypsinisation in the case of OV 632. CONCLUSIONS--OV 632 is unsuitable for routine clinical use in paraffin wax embedded material. MOC 31, however, would be a useful addition to a panel of antibodies in the differential diagnosis of mesothelioma and adenocarcinoma in large biopsy and resection specimens and necropsy material. Its value in small biopsy specimens remains to be assessed. Microwave pretreatment does not enhance the reactions with either antibody.

Full text

PDF
626

Images in this article

627Image
on p.627
627Image
on p.627
628Image
on p.628

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin M. B., Fechner R. E., Roggli V. L. Pleural malignant mesothelioma following Wilms' tumor. Am J Clin Pathol. 1986 Aug;86(2):227–230. doi: 10.1093/ajcp/86.2.227. [DOI] [PubMed] [Google Scholar]
  2. Brown R. W., Clark G. M., Tandon A. K., Allred D. C. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993 Apr;24(4):347–354. doi: 10.1016/0046-8177(93)90080-z. [DOI] [PubMed] [Google Scholar]
  3. Cuevas E. C., Bateman A. C., Wilkins B. S., Johnson P. A., Williams J. H., Lee A. H., Jones D. B., Wright D. H. Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies. J Clin Pathol. 1994 May;47(5):448–452. doi: 10.1136/jcp.47.5.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Delahaye M., Hoogsteden H. C., Van der Kwast T. H. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol. 1991 Oct;165(2):137–143. doi: 10.1002/path.1711650209. [DOI] [PubMed] [Google Scholar]
  5. Fleuren G. J., Coerkamp E. G., Nap M., vd Broek L. J., Warnaar S. O. Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas. Virchows Arch A Pathol Anat Histopathol. 1987;410(6):481–486. doi: 10.1007/BF00781682. [DOI] [PubMed] [Google Scholar]
  6. Frisman D. M., McCarthy W. F., Schleiff P., Buckner S. B., Nocito J. D., Jr, O'Leary T. J. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol. 1993 Mar;6(2):179–184. [PubMed] [Google Scholar]
  7. Koss M., Travis W., Moran C., Hochholzer L. Pseudomesotheliomatous adenocarcinoma: a reappraisal. Semin Diagn Pathol. 1992 May;9(2):117–123. [PubMed] [Google Scholar]
  8. Roggli V. L., Kolbeck J., Sanfilippo F., Shelburne J. D. Pathology of human mesothelioma. Etiologic and diagnostic considerations. Pathol Annu. 1987;22(Pt 2):91–131. [PubMed] [Google Scholar]
  9. Ruitenbeek T., Gouw A. S., Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med. 1994 Mar;118(3):265–269. [PubMed] [Google Scholar]
  10. Sheibani K., Esteban J. M., Bailey A., Battifora H., Weiss L. M. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol. 1992 Feb;23(2):107–116. doi: 10.1016/0046-8177(92)90231-q. [DOI] [PubMed] [Google Scholar]
  11. Sheibani K. Immunopathology of malignant mesothelioma. Hum Pathol. 1994 Mar;25(3):219–220. doi: 10.1016/0046-8177(94)90190-2. [DOI] [PubMed] [Google Scholar]
  12. Weiss L. M., Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum Pathol. 1993 Apr;24(4):345–346. doi: 10.1016/0046-8177(93)90079-v. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES